Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404086 | 0.70 | CHRM1 (0.56) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL6783753 | 0.70 | CYP2E1 (0.55) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6776019 | 0.67 | CHRM1 (0.64) | CHRM1ADRA1DADRA1A | |
| SCHEMBL7616080 | 0.64 | CHRM4 (0.71) | CHRM1ADRA1ACHRM2CHRM3CHRM4 | |
| SCHEMBL7611330 | 0.63 | CHRM1 (0.70) | CHRM1ADRA1ACHRM2CHRM3CHRM4 | |
| SCHEMBL7613541 | 0.61 | CHRM1 (0.58) | CHRM1CHRM2CHRM3 | |
| SCHEMBL6779518 | 0.60 | CHRM1 (1.00) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL6770818 | 0.60 | CHRNB2 (0.43) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL6770820 | 0.60 | CHRNB2 (0.43) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL6766318 | 0.60 | CHRNB2 (0.43) | CHRM1CHRM2CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6759419-B2 | NOOTROPIC AGENTS; BRAIN DISORDERS; ALZHEIMER'S DISEASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-07-06 | — | — | US | claimed |
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-06-19 | — | — | US | claimed |
| US-6759419-B2 | NOOTROPIC AGENTS; BRAIN DISORDERS; ALZHEIMER'S DISEASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-07-06 | — | — | US | disclosed |
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114491-A1 | Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same | CHRM1, CHRNA5, CHRNA7 | CHRM1 1/4885ADRA1D 26/4885ADRA1A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.